title: Introduction.
authors.affiliation: Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Blute
authors.forename: S J
authors.initials: SJ
authors.lastname: Jacobsen
authors.forename: S A
authors.initials: SA
authors.lastname: Kaplan
authors.forename: F C
authors.initials: FC
authors.lastname: Lowe
authors.forename: M P
authors.initials: MP
authors.lastname: O'Leary
authors.forename: W D
authors.initials: WD
authors.lastname: Steers
authors.forename: C G
authors.initials: CG
authors.lastname: Roehrborn
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D004791:Enzyme Inhibitors